An exploratory analysis led by Wendy A. Woodward suggested that patients with low or absent pretreatment circulating tumor cells (CTCs) had improved progression-free survival with ablation, while those with elevated CTCs did not benefit.

From the articleRandomized trial finds targeting individual metastases in oligometastatic breast cancer does not improve survivalAlso in Ablation Falls Short in Oligometastatic Breast Cancer Trial